Biogen INC BIOGEN INC ORD SHS
Biogen INC BIOGEN INC ORD SHS/ US09062X1037 /
0R1B
24/05/2024 18:25:10
|
Diferencia
-
|
Volumen |
Bid6:00:05 |
Ask6:00:05 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
218.75USD
|
-
|
1,014 Volumen de negocios: 110,398.48 |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
25.34 mil millonesUSD |
- |
21.69 |
Descripción de negocio
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies.
Consejo de gestión & Consejo de supervisión
CEO |
Christopher A. Viehbacher |
Consejo de gestión |
Michael McDonnell, Dr. Ginger Gregory, Rachid Izzar, Susan H. Alexander, Nicole Murphy, Priya Singhal |
Consejo de supervisión |
Caroline Dorsa, Eric K. Rowinsky, Jesus B. Mantas, Maria C. Freire, Stephen A. Sherwin, William A. Hawkins, Susan Langer, Christopher A. Viehbacher, Lloyd B. Minor |
Datos de la empresa
Nombre: |
Biogen Inc. |
Dirección: |
225 Binney Street,Cambridge, Massachusetts 02142, USA |
Teléfono: |
+1 781-464-2000 |
Fax: |
+1-617-679-2617 |
E-mail: |
-
|
Internet: |
www.biogen.com |
Industria: |
Biotechnology |
Sector: |
Biotechnology |
Subsector: |
Biotechnology |
Fin del año financiero: |
31/12 |
Acciones de libre circulación: |
72.20% |
Fecha de OPI: |
- |
Relación con inversores
Nombre: |
Karen Jewell |
IR teléfono: |
781-464-2442 |
IR-fax: |
- |
IR e-mail: |
IR@biogenidec.com
|
Accionistas mayoritarios
Otros |
|
48.93% |
PRIMECAP MANAGEMENT CO CA |
|
11.17% |
Vanguard Group |
|
9.90% |
BlackRock Inc. |
|
9.79% |
State Street Corporation |
|
4.77% |
"T. Rowe Price Investment Management, Inc." |
|
3.68% |
Wellington Management Group |
|
3.66% |
JP Morgan Chase & Co. |
|
3.44% |
GEODE CAPITAL MANAGEMENT LLC |
|
2.27% |
Otros |
|
2.40% |